The success of nanomedicine.

Abstract In recent years, the promise and prospects of nanomedicine have been controversially discussed. We here argue that nanomedicine has undeniably been successful, not only academically and preclinically, but also industrially and clinically. To ensure that we keep on making progress, we have to move away from over-focusing on nano and on materials, towards more holistic approaches that address real medical problems, in a realistic manner.

[1]  Gert Storm,et al.  The role of liposomes in clinical nanomedicine development. What now? Now what? , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Mauro Ferrari,et al.  Clinical Cancer Nanomedicine. , 2019, Nano today.

[3]  Scott E. McNeil,et al.  Evaluation of nanomedicines: stick to the basics , 2016, Nature Reviews Materials.

[4]  Kristofer J. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[5]  Heidi Ledford.  Bankruptcy filing worries developers of nanoparticle cancer drugs , 2016, Nature.

[6]  Fabian Kiessling,et al.  Smart cancer nanomedicine , 2019, Nature Nanotechnology.

[7]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[8]  Janice M. Reichert,et al.  A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.

[9]  Kinam Park.  The beginning of the end of the nanomedicine hype. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[10]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[11]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[12]  Fabian Kiessling,et al.  Cancer nanomedicine: Is targeting our target? , 2016, Nature reviews. Materials.

[13]  P. Grodzinski.  NCI Cancer Nanotechnology Centers of Excellence (CCNEs) - A full story to set the record straight. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Robert K. Stuart,et al.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Twan Lammers,et al.  Macro-nanomedicine: Targeting the big picture. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Celia N. Cruz,et al.  The evolving landscape of drug products containing nanomaterials in the United States. , 2017, Nature nanotechnology.

[17]  C. Sheridan.  Billion-dollar deal propels RNAi to CNS frontier , 2019, Nature Biotechnology.

[18]  T. Park,et al.  Diverse Applications of Nanomedicine , 2017, ACS nano.

[19]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.